| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients RS Herbst, JC Soria, M Kowanetz, GD Fine, O Hamid, MS Gordon, ... Nature 515 (7528), 563-567, 2014 | 5337 | 2014 |
| TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ... Nature 554 (7693), 544-548, 2018 | 3728 | 2018 |
| Early childhood development coming of age: science through the life course MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ... The Lancet 389 (10064), 77-90, 2017 | 2697 | 2017 |
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer T Powles, JP Eder, GD Fine, FS Braiteh, Y Loriot, C Cruz, J Bellmunt, ... Nature 515 (7528), 558-562, 2014 | 2587 | 2014 |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2074 | 2017 |
| Top 10 challenges in cancer immunotherapy PS Hegde, DS Chen Immunity 52 (1), 17-35, 2020 | 1408 | 2020 |
| A concise guide to cDNA microarray analysis P Hegde, R Qi, K Abernathy, C Gay, S Dharap, R Gaspard, JE Hughes, ... Biotechniques 29 (3), 548-562, 2000 | 1377 | 2000 |
| Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 … T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ... The Lancet 391 (10122), 748-757, 2018 | 1356 | 2018 |
| Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab DR Gandara, SM Paul, M Kowanetz, E Schleifman, W Zou, Y Li, ... Nature medicine 24 (9), 1441-1448, 2018 | 1083 | 2018 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 1022 | 2018 |
| The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition PS Hegde, V Karanikas, S Evers Clinical Cancer Research 22 (8), 1865-1874, 2016 | 832 | 2016 |
| Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma JJ Wallin, JC Bendell, R Funke, M Sznol, K Korski, S Jones, G Hernandez, ... Nature communications 7 (1), 1-8, 2016 | 635 | 2016 |
| Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study DF McDermott, JA Sosman, M Sznol, C Massard, MS Gordon, O Hamid, ... Journal of Clinical Oncology 34 (8), 833-842, 2016 | 582 | 2016 |
| A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer W Xia, S Bacus, P Hegde, I Husain, J Strum, L Liu, G Paulazzo, L Lyass, ... Proceedings of the National Academy of Sciences 103 (20), 7795-7800, 2006 | 427 | 2006 |
| Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics PS Hegde, JJ Wallin, C Mancao Seminars in cancer biology 52, 117-124, 2018 | 372 | 2018 |
| Activation of peroxisome proliferator–activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid … U Risérus, D Sprecher, T Johnson, E Olson, S Hirschberg, A Liu, Z Fang, ... Diabetes 57 (2), 332-339, 2008 | 359 | 2008 |
| Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of … T Sandmann, R Bourgon, J Garcia, C Li, T Cloughesy, OL Chinot, W Wick, ... Journal of clinical oncology 33 (25), 2735, 2015 | 316 | 2015 |
| Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade RJ Motzer, R Banchereau, H Hamidi, T Powles, D McDermott, MB Atkins, ... Cancer cell 38 (6), 803-817. e4, 2020 | 312 | 2020 |
| Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy M Mayoux, A Roller, V Pulko, S Sammicheli, S Chen, E Sum, C Jost, ... Science translational medicine 12 (534), eaav7431, 2020 | 289 | 2020 |
| Interplay of transcriptomics and proteomics PS Hegde, IR White, C Debouck Current opinion in biotechnology 14 (6), 647-651, 2003 | 286 | 2003 |
Gregg FineStork TherapeuticsVerified email at storktherapeutics.com
